JOVANA
Library Glossary Getting Started Three Levels Fields How it works Mission
Join the mission
All guides

Efficacy, Emax, and the Full Spectrum of Agonists

Drugs are not just "on" or "off." Between a full agonist and a silent antagonist lies a rich spectrum — partial agonists, inverse agonists, and the surprising idea that you can have spare receptors. This guide maps that spectrum.

A dial, not a switch

The cleanest way to picture efficacy is the ceiling of a drug's dose–response curve: the Emax. A full agonist drives the system to its biological maximum. A partial agonist binds the same receptor, activates it, but can never push past, say, 50% of the maximum no matter how much you give. Its ceiling is lower — and that lower ceiling, not its potency, is what defines it.

This connects straight back to intrinsic activity from the first guide. A full agonist has intrinsic activity near 1; a partial agonist sits somewhere in between, say 0.3 to 0.7; a pure antagonist is 0. The spectrum is continuous, and chemistry can move a molecule along it.

Below zero: inverse agonists

Some receptors are not silent when empty — they have baseline activity, firing a little even with no agonist around. Against such a receptor, a plain antagonist does nothing visible: it blocks agonists but leaves the baseline untouched. An inverse agonist goes further. It binds and actively pushes the receptor below its resting level, switching off even the baseline signal. On the intrinsic-activity scale it has a *negative* value.

Spectrum of effect on a receptor with baseline activity:

  inverse agonist   -- pushes BELOW baseline   (intrinsic activity < 0)
  antagonist        -- holds AT baseline        (intrinsic activity = 0)
  partial agonist   -- raises PART way up        (0 < i.a. < 1)
  full agonist      -- raises to MAXIMUM         (intrinsic activity = 1)

All four can bind the SAME site with similar affinity.
What differs is the direction and size of the push.
One binding site, four behaviors — the full efficacy spectrum from inverse agonist to full agonist.

Spare receptors and biased signaling

Here is a twist that surprises newcomers: in some tissues you do not need to occupy every receptor to get the maximum response. There is a receptor reserve — "spare" receptors. A full agonist may hit Emax while occupying only a fraction of them. One practical consequence is that occupancy and effect are not the same percentage — a drug at 20% occupancy might already give 80% of the effect. This decouples the binding curve from the response curve in a way you must watch for when interpreting data.

Modern pharmacology adds one more dimension: biased agonism. A single receptor can trigger several downstream pathways, and a clever agonist may activate one pathway strongly while barely touching another. "Efficacy" then becomes pathway-specific — a drug can be a full agonist for the beneficial signal and a partial agonist for the harmful one. This is one of the most active frontiers in receptor drug design.